Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CING with free AI briefings, catalyst countdowns, and dilution alerts.

CING · Cingulate Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$28.4M Cash on Hand
13.3mo Cash Runway
9.8% Short Interest
$21.2 Analyst Target (5)
Follow CING by email Get an email when CING reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CING, unsubscribe in one click. Privacy

📣 What CING Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CTx-1301 - Dexmethylphenidate 12.5mg ADHD Phase 3 · NCT05924594 Suspended
CTx-1301-Dexmethylphenidate 12.5 mg (titration… ADHD Phase 3 · NCT05286762 Completed
Dexmethylphenidate ADHD Phase 1/2 · NCT04138498 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CING holds $28.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.4M/quarter from operations, an estimated runway of 13.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 78 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CING files for a raise →

👥 Who Owns CING

Insiders 1.8% Other 5%+ holders 26.5% Institutions (40 holders) 13.4% Public and other holders 58.3%
HolderTypeShares% of sharesAs of
Falcon Creek Capital Advisor LLC 5%+ holder (13D) 3,856,766 26.52% 2026-03-24
Kestra Advisory Services, LLC Institution (13F) 156,500 1.08% 2026-09-30
Geode Capital Management, LLC Institution (13F) 152,820 1.05% 2026-09-30
Peter J. Werth
Director · +67,490 options
Insider 117,541 0.81% 2026-02-06
Chicago Partners Investment Group LLC Institution (13F) 110,737 0.76% 2026-09-30
North Star Investment Management Corp Institution (13F) 100,000 0.69% 2026-09-30
Thomas Jeffrey Hargroves
Director · +112,821 options
Insider 97,468 0.67% 2026-02-13
Simplex Trading, LLC Institution (13F) 70,978 0.49% 2026-09-30
Shane J. Schaffer
Chief Executive Officer, Director · +618,101 options
Insider 14,251 0.10% 2026-03-09
Jennifer L. Callahan
EVP and CFO · +236,886 options
Insider 13,961 0.10% 2026-03-09
Matthew Brams
EVP and Chief Medical Officer · +168,158 options
Insider 8,157 0.06% 2026-03-09
Raul R. Silva
EVP and CSO · +189,742 options
Insider 4,645 0.03% 2026-03-09

Share count 14,541,826 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-30
filed 2026-10-02
Silva Raul R.
Option award (A) 4,293 – –
2026-07-16
filed 2026-07-20
Schaffer Shane J.
Option award (A) 197,650 – –
2026-07-16
filed 2026-07-20
Silva Raul R.
Option award (A) 53,600 – –
2026-07-16
filed 2026-07-20
Silva Raul R.
Option award (A) 26,400 – –
2026-07-16
filed 2026-07-20
Werth Peter J.
Option award (A) 20,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full CING picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CING and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.